Journal
GYNECOLOGIC ONCOLOGY
Volume 160, Issue 1, Pages 45-50Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ygyno.2020.09.052
Keywords
Minimally invasive surgery; Ovarian cancer; Interval debul king surgery; Hyperthermic intraperitoneal chemotherapy
Categories
Ask authors/readers for more resources
This study demonstrated the feasibility of using MIS for HIPEC in EOC patients undergoing IDS after NACT, with similar outcomes to LAP. Shorter hospital stay was observed in the MIS group compared to LAP, with no significant differences in other peri-operative outcomes.
Objective. To determine pert-operative outcomes in women with advanced epithelial ovarian cancer (EOC) undergoing interval debulking surgery (IDS) with hyperthermic intraperitoneal chemotherapy (HIPEC) via minimally invasive interval debulking surgery (MIS) or laparotomy (LAP). Methods. A single institution, retrospective cohort study was performed in women with EOC who underwent IDS with HIPEC from 2017 to 2019 via MIS or LAP. Peri-operative outcomes were compared using univariate analysis. Results. In total, 50 eligible women were identified; ten (20.0%) underwent MIS + HIPEC and 40 (80.0%) LAP + HIPEC The median age of patients in the MIS group was 71.1 vs. 64.2 years in LAP (p = 0.031). There was no significant difference in pre-operative complete radiographic response following NACT (p = 0.18). Notably, there was no difference in the rate of RO resection (70.0% vs. 77.5%: p = 0.39). There was no significant difference in KU admission, estimated blood loss, operative time, or use of vasopressors between the cohorts. Similarly, there was no difference in 30-day adverse events for MIS vs. LAP, but length of stay was decreased for those who underwent minimally invasive procedures (3 vs. 4 days, p = 0.016). Time to initiation of chemotherapy following surgery was not significantly different between groups (26.2 days vs 32.0 days, p = 0.090). With median follow-up of 15.1 months, there was no difference in recurrence free survival (median 15.0 vs 17.2 months log-rank, p = 0.30) for MIS vs. LAP. Conclusions. In this retrospective cohort study, we demonstrate that in women with advanced EOC. HIPEC with MIS at the time of IDS following NACT is feasible. Our institutional experience demonstrates similar rates of RO cytoreduction, compared to LAP. An MIS approach should not prevent surgeons from utilizing HIPEC where indicated for management of advanced EOC. (C) 2020 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available